Fig. 3: Progression-free survival in subgroups of interest.

Progression-free survival from first randomization (R1) according to 1q alterations and concomitant cytogenetic risk (A–C), LDH levels (D and E), ISS (F–H), and circulating tumor cells (CTCs) levels (I).